Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 3, Number 2—June 1997
Synopsis

Is Creutzfeldt-Jakob Disease Transmitted in Blood?

Maura N. Ricketts*Comments to Author , Neil R. Cashman†, Elizabeth E. Stratton*, and Susie ElSaadany*
Author affiliations: *Laboratory Centre for Disease Control, Health Canada, Ottawa, Ontario, Canada; and †Montreal Neurological Institute, Montreal, Canada

Main Article

Table 1

Transmissible cases of Creutzfeldt-Jakob Disease

Mode of infection No.
of patients Agent entry
into brain Mean incubation period (range)
INSTRUMENTATION
Neurosurgery 4 Intracerebral 20 months (15-28)
Stereotactic EEG 2 Intracerebral 18 months (16-20)
TISSURE TRANSFER
Corneal transplant 2 Optic nerve 17 months (16-18)
Dura mater implant 25 Cerebral surface 5.5 years (1.5-12))
TISSURE EXTRACT
TRANSFER
Growth hormone 76 Hematogenous 12 years (5-30)
Gonadotrophin 4 Hematogenous 13 years (12-16)

EEG = electroencephalogram
Table taken from (27)

Main Article

References
  1. Masters  CL, Harris  JO, Gajdusek  C, Gibbs  CJ, Bernoulli  C, Asher  DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5:177–88. DOIPubMedGoogle Scholar
  2. Brown  P, Cathala  F, Raubertas  RF, Gajdusek  DC, Castaigne  P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15 year investigation in France and review of the world literature. Neurology. 1987;37:895–904.PubMedGoogle Scholar
  3. Will  RG. Incidence of Creutzfeldt-Jakob disease in the European Community. In: Gibbs CJ Jr, editor. Bovine Spongiform Encephalopathy: The BSE Dilemma. New York: Springer-Verlag 1996:364-74.
  4. World Health Organization consultation on clinical and neuropathological characteristics of the new variant of CJD and other human and animal TSEs. Geneva: WHO, 1996.
  5. Creutzfeldt-Jakob disease in Australia: first annual report. Melbourne: The National CJD Registry, 1996.
  6. Stratton  E, Ricketts  MN, Gully  PR. Creutzfeldt-Jakob disease in Canada. CCDR. 1996;22:57–61.
  7. Kovanen  J, Haltia  M. Descriptive epidemiology of Creutzfeldt-Jakob disease in Finland. Acta Neurol Scand. 1980;77:474–80. DOIGoogle Scholar
  8. Holman  RC, Khan  AS, Kent  J, Strine  TW, Schonberger  LB. Epidemiology of Creutzfeldt-Jakob disease in the United States, 1979-1990: analysis of national mortality data. Neuroepidemiology. 1995;14:174–81. DOIPubMedGoogle Scholar
  9. de Silva  R. Human spongiform encephalopathy: clinical presentation and diagnostic tests. In: Baker H, Ridley RM, editors. Methods in molecular medicine: prion diseases. Totawa (NJ): Humana Press Inc; 1996:15-33.
  10. Kretzschmar  HA, Ironside  JW, DeArmond  SJ, Tateishi  J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996;53:913–20.PubMedGoogle Scholar
  11. Ironside  JW. Neuropathological diagnosis of human prion disease. In: Baker H, Ridley RM, editors. Methods in molecular medicine: prion diseases. Totawa (NJ): Humana Press Inc; 1996:35-57.
  12. Parchi  P, Castellani  R, Capellari  S, Ghetti  B, Young  K, Chen  SG, Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:767–78. DOIPubMedGoogle Scholar
  13. Collinge  J, Sidle  DC, Meads  J, Ironside  J, Hill  AF. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature. 1996;383:685–90. DOIPubMedGoogle Scholar
  14. Zerr  I, Bodemer  M, Otto  M, Poser  S, Wind  IO, Kretzschmar  HA, Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet. 1996;348:846–9. DOIPubMedGoogle Scholar
  15. Hsich  G, Kenney  K, Gibbs  CJ, Lee  KH, Harrington  MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335:924–30. DOIPubMedGoogle Scholar
  16. Manuelidis  L. The dimensions of Creutzfeldt-Jakob disease. Transfusion. 1994;34:915–28. DOIPubMedGoogle Scholar
  17. Ozel  M, Diringer  H. Small virus-like structure in fractions from scrapie hamster brain. Lancet. 1994;343:894–5. DOIPubMedGoogle Scholar
  18. Brown  P, Preece  MA, Will  RG. "Friendly Fire" in medicine: hormones, homografts and CJD. Lancet. 1992;340:24–7. DOIPubMedGoogle Scholar
  19. Lasmézas  CI, Deslys  JP, Robain  O, Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science. 1997;275:402–5. DOIPubMedGoogle Scholar
  20. Collinge  J, Palmer  MS, Dryden  AJ. Genetic pre-disposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;337:1441–2. DOIPubMedGoogle Scholar
  21. Brown  P, Gajdusek  DC. The Human Spongiform Encephalopathies: Kuru, Creutzfeldt-Jakob Disease, and the Gerstmann-Straussler-Scheinker Syndrome. In: Chesebro BW, editor. Current topics in microbiology and immunology, vol 172. New York: Springer-Verlag, 1991:1-20.
  22. Will  RG, Ironside  JW, Zeidler  M, Cousens  SN, Estibeiro  K, Alperovitch  A, A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921–5. DOIPubMedGoogle Scholar
  23. Gajdusek  DC, Gibbs  CJ, Alpers  M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature. 1966;209:794–6. DOIPubMedGoogle Scholar
  24. Gibbs  CJ Jr, Gajdusek  DC, Asher  DM, Alpers  MP, Beck  E, Daniel  PM, Creutzfeldt-Jakob disease (subacute spongiform encephalopathy): transmission to the chimpanzee. Science. 1968;161:388–9. DOIPubMedGoogle Scholar
  25. Duffy  P, Wolf  J, Collins  G, DeVoe  AG, Streeten  B, Cowen  D. Possible person-person transmission of CJD. N Engl J Med. 1974;290:692.PubMedGoogle Scholar
  26. Liberski  PP, Yanagihara  R, Gibbs  CJ, Gajdusek  DC. Spread of Creutzfeldt-Jakob disease virus along visual pathways after intra ocular inoculation. Arch Virol. 1990;111:141–7. DOIPubMedGoogle Scholar
  27. Maneulidis  EE, Maneulidis  L. Experiments on maternal transmission of Creutzfeldt-Jakob disease in guinea pigs. Proc Soc Exp Biol Med. 1979;160:233–6.PubMedGoogle Scholar
  28. Brown  P. Environmental causes of human spongiform encephalopathy. In: Baker H, Ridley RM, editors. Methods in molecular medicine: prion diseases. Totawa (NJ): Humana Press Inc; 1996:139-54.
  29. Bernoulli  C, Siegfried  J, Baumgartner  G, Regli  F, Rabinowicz  T, Gajdusek  DC, Danger of accidental person-to-person transmission of CJD by surgery. Lancet. 1977;1:478–9. DOIPubMedGoogle Scholar
  30. Brown  P. Transmissible human spongiform encepha-lopathy (infectious cerebral amyloidosis): Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker's syndrome and kuru. In: Calne DB, editor. Neurode-generative diseases. Philadelphia: 1994:839-76.
  31. Foncin  J, Gaches  J, Cathala  F, El Sharif  E, Le Beau  J. Transmission iatrogene interhumaine possible de maladie de Creutzfeldt-Jakob disease avec atteinte des grains du cervelet. Rev Neurol. 1980;136:280.
  32. Will  RG, Matthews  WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 1982;45:235–8. DOIPubMedGoogle Scholar
  33. Nevin  S, McMenemy  WH, Berhman  D, Jones  DP. Subacute spongiform encephalopathy: a subacute form of encephalopathy attributable to vascular dysfunction (spongiform cerebral atrophy). Brain. 1960;83:519–64. DOIPubMedGoogle Scholar
  34. Prichard  J, Thadani  V, Kalb  R, Manuelidis  E, Holder  J. Rapidly progressive dementia in a patient who received a cadaveric dura mater graft. MMWR Morb Moral Wkly Rep 1987;36:49-50, 55.
  35. Centers for Disease Control. Update: Creutzfeldt-Jakob disease in a second patient who received a cadaveric dura mater graft. MMWR Morb Moral Wkly Rep 1989;38:37-8, 43.
  36. Esmonde  T, Lueck  CJD, Symon  L, Duchen  LW, Will  RG. Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases. J Neurol Neurosurg Psychiatry. 1994;56:999–1000. DOIGoogle Scholar
  37. Centers for Disease Control. Fatal degenerative neurologic disease in patients who received pituitary derived human growth hormone. MMWR Morb Moral Wkly Rep 1985;34:359-60, 365-6.
  38. Cochius  JJ, Hyman  N, Esiri  MM. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotropin, a second case. J Neurol Neurosurg Psychiatry. 1992;55:1094–5. DOIPubMedGoogle Scholar
  39. Brown  P, Cervenakova  L, Goldfarb  LG, McCombie  WR, Rubenstein  R, Will  RG, Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurology. 1994;44:291–3.PubMedGoogle Scholar
  40. Manuelidis  EE, Kim  JH, Mericangas  JR, Manuelidis  L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet. 1985;2:896–7. DOIPubMedGoogle Scholar
  41. Tateishi  J. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice. Lancet. 1985;2:1074. DOIPubMedGoogle Scholar
  42. Brown  P, Gibbs  CJ, Rodgers-Johnson  P, Asher  DM, Sulima  MP, Bacote  A, Human spongiform encephalopathy: the NIH series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994;44:513–5. DOIGoogle Scholar
  43. Lavelle  GC, Sturman  L, Hadlow  WJ. Isolation from mouse spleen of cell populations with high specific infectivity for scrapie virus. Infect Immun. 1972;5:319–23.PubMedGoogle Scholar
  44. Kuroda  Y, Gibbs  CJ, Amyx  HL, Gajdusek  DC. Creutzfeldt-Jakob disease in mice: persistent viraemia and preferential replication of virus in low density lymphocytes. Infect Immun. 1983;41:154–61.PubMedGoogle Scholar
  45. Czub  M, Braig  HR, Blode  H, Diringer  H. The major protein of SAF is absent from spleen and thus not an essential part of the scrapie agent. Arch Virol. 1986;91:83–6. DOIPubMedGoogle Scholar
  46. Manuelidis  EE, Gorgacs  EJ, Manuelidis  L. Viraemia in experimental Creutzfeldt-Jakob disease. Science. 1978;200:1069–71. DOIPubMedGoogle Scholar
  47. Deslys  JP, Lasmezas  C, Dormont  D. Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease [letter]. Lancet. 1994;343:848–9. DOIPubMedGoogle Scholar
  48. Matthews  WB. Transmission of Creutzfeldt-Jakob disease [letter]. Lancet. 1994;343:1575–6. DOIPubMedGoogle Scholar
  49. Creange  A, Gray  F, Cesaro , Adle-Biassette  H, Duvoux  C, Cherqui  D, . Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol. 1995;38:269–72. DOIPubMedGoogle Scholar
  50. Klein  R, Dumble  LJ. Transmission of Creutzfeldt-Jakob disease by blood transfusion. Lancet. 1993;341:768. DOIPubMedGoogle Scholar
  51. Collins  S, Masters  CL. Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the Australian perspective. Med J Aust. 1996;164:598–602.PubMedGoogle Scholar
  52. Will  RG. Surveillance of prion diseases in humans. In: Baker H, Ridley RM, editors. Methods in molecular medicine: prion diseases. Totawa (NJ): Humana Press Inc., 1996;119-37.
  53. Reingold  A, Rothrock  G, Starr  M, Reilly  K, Vugia  D, Waterman  S, Surveillance for Creutzfeldt-Jakob disease-United States. MMWR Morb Mortal Wkly Rep. 1996;45:665–8.PubMedGoogle Scholar
  54. Raubertas  RF, Brown  P, Cathala  F, Brown  I. The Question of clustering of Creutzfeldt-Jakob disease. Am J Epidemiol. 1989;129:146–54.PubMedGoogle Scholar
  55. Kondo  K, Kuroiwa  Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol. 1982;11:377–81. DOIPubMedGoogle Scholar
  56. Will  RG. Epidemiological surveillance of Creutzfeldt-Jakob disease in the United Kingdom. Eur J Epidemiol. 1991;7:460–5. DOIPubMedGoogle Scholar
  57. Esmonde  TFG, Will  RG, Slattery  JM, Knight  R, Harries-Jones  R, de Silva  R, Creutzfeldt-Jakob disease and blood transfusion. Lancet. 1993;341:205–7. DOIPubMedGoogle Scholar
  58. Harries-Jones  R, Knight  R, Will  RG, Cousens  S, Smith  PG, Matthews  WB. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry. 1988;51:1113–9. DOIPubMedGoogle Scholar
  59. Esmonde  TFG, Ireland  BN, Will  RG, Ironside  J. Creutzfeldt-Jakob disease: A case-control study. [Abstract 260P]. Neurology. 1994;44:A193.
  60. Davanipour  Z, Alter  M, Sobel  E, Asher  D, Gajdusek  DC. Creutzfeldt-Jakob disease: possible medical risk factors. Neurology. 1985;35:1483–6.PubMedGoogle Scholar
  61. Walter  SD. Determination of significant relative risks and optimal sampling procedures in prospective and retrospective comparative studies of various sizes. Am J Epidemiol. 1977;105:387–97.PubMedGoogle Scholar
  62. Wientjens  DPWM, Davinipour  Z, Hofman  A, Kondo  K, Matthews  WB, Will  RG, Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology. 1996;46:1287–91.PubMedGoogle Scholar
  63. Operskalski  EA, Mosley  JW. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet. 1995;346:1223. DOIGoogle Scholar
  64. Schlesselman  JJ, Stolley  PD. Sources of bias. In: Schlesselman JJ, editor. Case-control studies: design, conduct, analysis. New York: Oxford University Press, 1982:124-43.
  65. Heye  N, Hensen  S, Muller  N. Creutzfeldt-Jakob disease and blood transfusion. Lancet. 1994;343:298–9. DOIPubMedGoogle Scholar
  66. Brown  P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol. 1995;2:472–7.PubMedGoogle Scholar
  67. Deslys  JP, Lasmezas  CI, Billette de Villemeur  T, Jaegly  A, Dormont  D. Creutzfeldt-Jakob disease. Lancet. 1996;347:1332. DOIPubMedGoogle Scholar

Main Article

Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external